C

아미코젠

092040KOSDAQ기타 식품 제조업

40.8 / 100

Reference Date: 2026-07-24

Financial Score5.0 / 40
News Sentiment18.8 / 25
Momentum2.0 / 20
Disclosure15.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 27.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Amicozen is an industrial biotech company specializing in developing enzymes for antibiotic production and health care materials using its proprietary gene evolution technology. Key products include N-acetylglucosamine, phytin, and collagen peptides, with expansion into endolysin enzyme business through collaboration with Lysando AG since 2020.

Number of Employees

228people

Average Salary

49.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 12.074.0Point
PBR
0.91Industry Average 0.541.0Point

1.7x industry avg (risky)

ROE
-27.74Industry Average 2.720.0Point

Well below industry avg

Debt Ratio
57.69Industry Average 11.910.0Point

4.8x industry avg (risky)

Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼33.6% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼293.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -22.7% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 0Negative 1Average Sentiment Score 75

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 1,233Won52-week high 4,22052-week low 1,115
1-month return0.0Point

1m -27.21% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 3Neutral 3Negative 0
  • Positive[기재정정]주요사항보고서(유상증자결정)2026-07-15
  • Positive[기재정정]경영권변경등에관한계약체결2026-07-15
  • Neutral[기재정정]신규시설투자등2026-06-30
  • Positive경영권변경등에관한계약체결2026-06-29
  • Neutral주주명부폐쇄기간또는기준일설정2026-06-25